Xenothera is a technology company.
Xenothera has raised $21.0M across 1 funding round.
Xenothera has raised $21.0M in total across 1 funding round.
Xenothera has raised $21.0M in total across 1 funding round.
Xenothera's investors include Ankaa Ventures.
Xenothera is a French biotechnology company headquartered in Nantes, specializing in innovative glyco-humanized polyclonal antibody (GH-pAb) therapies for immunology, infectious diseases, oncology, transplantation, and onco-hematology.[1][2][3] It develops treatments targeting serious diseases through a platform combining animal genetics and immunological expertise, producing hyperimmune sera with enhanced properties like reduced adverse effects and strong neutralization capabilities, as demonstrated in COVID-19 applications with XAV-19.[1][3][4] The company serves patients with unmet needs in these areas, solving problems like limited efficacy and safety in traditional immunotherapies; it has treated over 400 patients, with four products in clinic—including proof-of-concept for LIS1 in transplantation and XAV-19 in COVID—and ongoing oncology trials like XON7 (phase I/II FIPO for solid tumors) and LIS22 (phase I/II PALT1 for peripheral T-cell lymphoma).[3][6] Growth momentum includes recent 2025 advances in oncology, €4 million non-dilutive France 2030 funding, and its own biomanufacturing site supported by regional and European initiatives.[3][6]
Founded on June 30, 2014, Xenothera emerged from expertise in animal genetics—specifically genetically modified pigs—and immunological processes to pioneer glyco-humanized antibodies.[2][3] The company's backstory ties to addressing gaps in passive immunotherapy, renovating it with a new generation of polyclonal sera engineered for better biological activity.[1] Early traction came during the COVID resurgence, where XAV-19 showed strong neutralization against variants like Omicron in published data (Vanhove et al., 2020-2022), marking a pivotal moment.[1] This built toward oncology and transplantation focus, with LIS1 achieving proof-of-concept in humans and rapid clinic entry for multiple products.[3]
Xenothera rides the wave of next-generation immunotherapy, particularly glyco-engineered antibodies and xenotransplantation, amid rising demand for precise, multi-target treatments in oncology and infectious diseases where monotherapies fall short.[1][4][6] Timing aligns with post-COVID urgency for rapid-response antivirals (e.g., XAV-19) and oncology breakthroughs, fueled by market forces like aging populations, antimicrobial resistance, and €4M+ public funding from France 2030 and EIC.[3][4][6] It influences Europe's biotech ecosystem by validating deeptech platforms—supported by Atlanpole incubation—and advancing xenotransplantation, potentially reshaping organ shortages and solidifying France's biotech hub status in Nantes.[3][6]
Xenothera is poised for oncology acceleration, with 2025 milestones like PALT1 trial progress for LIS22 and reaffirmed xenotransplantation commitment signaling pipeline expansion.[6] Trends like multispecific antibodies and AI-optimized glyco-engineering will shape its path, potentially yielding phase II/III data and partnerships amid €4M funding boosts.[5][6] Its influence may evolve from niche innovator to ecosystem leader, driving responsive care in immunology and beyond—reinforcing its start as a biotech trailblazer tackling immunotherapy's toughest challenges.[1][2]
Xenothera has raised $21.0M across 1 funding round. Most recently, it raised $21.0M Series C in June 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2021 | $21.0M Series C | Ankaa Ventures |